PTPN1 and atherosclerosis: Our own studies have demonstrated that the myeloid-specific genetic deletion of PTP1B in an ApoE−/− mouse model of atherosclerosis protected against atherosclerosis development by increasing the circulating levels of the anti-inflammatory IL-10 cytokines and the vasodilator PGE2, along with decreasing the circulating levels of cholesterol and triglycerides, defending against atherosclerotic plaque formation [63].